Dianthus Therapeutics, Inc. /DE/

Developing selective antibody therapies for severe autoimmune diseases.

DNTH | US

Overview

Corporate Details

ISIN(s):: US2528281080 (+1 more)
LEI:
Country:: United States of America
Address:: 7 TIMES SQUARE, 10036 NEW YORK
Website:: https://dianthustx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies for severe autoimmune diseases. The company focuses on designing and engineering potentially best-in-class monoclonal antibodies with improved potency, high selectivity, and extended half-lives. Its lead candidate, claseprubart (DNTH103), is an antibody that selectively targets the active C1s complement protein. The pipeline also includes DNTH212, a bifunctional inhibitor targeting Type 1 IFN suppression and B cell modulation. Dianthus's therapeutic approach aims to enable less frequent and more convenient self-administered subcutaneous injections, with the goal of improving clinical outcomes and quality of life for patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Dianthus Therapeutics, Inc. /DE/ filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Dianthus Therapeutics, Inc. /DE/

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Dianthus Therapeutics, Inc. /DE/ via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Labomar A CDMO developing custom supplements, medical devices & cosmetics for third-party clients.	Italy	LBM
Laboratorio Farmaceutico Erfo Full-service contract manufacturer of private label supplements and medical devices.	Italy	ERFO
Laboratorio Reig Jofre S.A. A pharmaceutical company making essential health products accessible in over 70 countries.	Spain	RJF
Laboratorios Farmaceuticos Rovi S.A. Integrated pharma firm developing prescription drugs and offering contract manufacturing services.	Spain	ROVI
LakeShore Biopharma Co., Ltd. Develops vaccines and therapeutic biologics for infectious diseases and cancer.	United States of America	LSB
Lantern Pharma Inc. Leverages AI and machine learning to discover and develop targeted cancer therapies.	United States of America	LTRN
Lantheus Holdings, Inc. Develops radiopharmaceutical diagnostics and therapies to help clinicians fight disease.	United States of America	LNTH
LAVA Therapeutics NV Develops bispecific gamma delta T cell engagers for solid and hematologic cancers.	United States of America	LVTX
Lavipharm S.A. Develops & distributes Rx/OTC medicines, supplements & cosmetics for key therapeutic areas.	Greece	LAVI
LB PHARMACEUTICALS INC Clinical-stage biopharma developing oral therapies for neuropsychiatric diseases like schizophrenia.	United States of America	LBRX